Healthcare Industry News: IIb/IIIa

Biopharmaceuticals

News Release - October 25, 2011

Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results

Source: Eli Lilly

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: Eli Lilly
Search: Xigris
Search: drotrecogin alfa
Search: septic shock

Related News Items

Lilly Completes Acquisition of AtaiBeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

Lilly to Acquire AtaiBeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions

Healthcare Industry NewsFeed

FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!